Genetic and clinical predictors of voriconazole pharmacokinetics and hepatotoxicity: focused on CYP2C19 normal and intermediate metabolizers.

doi:10.1093/jac/dkag065

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Genetic and clinical predictors of voriconazole pharmacokinetics and hepatotoxicity: focused on CYP2C19 normal and intermediate metabolizers.

The Journal of antimicrobial chemotherapy - 2 Feb 2026

Li Hui, Lu Qiuya, Xu Beiming, Li Aiqin, Fang Jie, He Xiaoshuang, Bian Xiaolan

Abstract excerpt

BACKGROUND: Voriconazole is recommended as first-line therapy for invasive fungal infections but exhibits substantial pharmacokinetic (PK) variability and hepatotoxicity. Although CYP2C19 polymorphisms partially explain this variability, evidence regarding additional genetic determinants remains inconsistent. Studies integrating genetic and clinical factors for voriconazole PK and hepatotoxicity are limited....

Read the complete abstract on PubMed